Read the associated blogpost for a detailed description of how this dataset was prepared; plus extra code for producing animated maps.

Context

The 2019 Novel Coronavirus (COVID-19) continues to spread in countries around the world. This dataset provides daily updated number of reported cases & deaths in Germany on the federal state (Bundesland) and county (Landkreis/Stadtkreis) level. In April 2021 I added a dataset on vaccination progress. In addition, I provide geospatial shape files and general state-level population demographics to aid the analysis.

Content

The dataset consists of thre main csv files: covid_de.csv, demgraphics_de.csv, and covid_de_vaccines.csv. The geospatial shapes are included in the de_state.* files. See the column descriptions below for more detailed information.

• covid_de.csv: COVID-19 cases and deaths which will be updated daily. The original data are being collected by Germany's Robert Koch Institute and can be download through the National Platform for Geographic Data (the latter site also hosts an interactive dashboard). I reshaped and translated the data (using R tidyverse tools) to make it better accessible. This blogpost explains how I prepared the data, and describes how to produces animated maps.

• demographics_de.csv: General Demographic Data about Germany on the federal state level. Those have been downloaded from Germany's Federal Office for Statistics (Statistisches Bundesamt) through their Open Data platform GENESIS. The data reflect the (most recent available) estimates on 2018-12-31. You can find the corresponding table here.

• covid_de_vaccines.csv: In April 2021 I added this file that contains the Covid-19 vaccination progress for Germany as a whole. It details daily doses, broken down cumulatively by manufacturer, as well as the cumulative number of people having received their first and full vaccination. The earliest data are from 2020-12-27.

• de_state.*: Geospatial shape files for Germany's 16 federal states. Downloaded via Germany's Federal Agency for Cartography and Geodesy . Specifically, the shape file was obtained from this link.

Column Description

COVID-19 dataset covid_de.csv:

• state: Name of the German federal state. Germany has 16 federal states. I removed converted special characters from the original data.

• county: The name of the German Landkreis (LK) or Stadtkreis (SK), which correspond roughly to US counties.

• age_group: The COVID-19 data is being reported for 6 age groups: 0-4, 5-14, 15-34, 35-59, 60-79, and above 80 years old. As a shortcut the last category I'm using "80-99", but there might well be persons above 99 years old in this dataset. This column has a few NA entries.

• gender: Reported as male (M) or female (F). This column has a few NA entries.

• date: The calendar date of when a case or death were reported. There might be delays that will be corrected by retroactively assigning cases to earlier dates.

• cases: COVID-19 cases that have been confirmed through laboratory work. This and the following 2 columns are counts per day, not cumulative counts.

• deaths: COVID-19 related deaths.

• recovered: Recovered cases.

Demographic dataset demographics_de.csv:

• state, gender, age_group: same as above. The demographic data is available in higher age resolution, but I have binned it here to match the corresponding age groups in the covid_de.csv file.

• population: Population counts for the respective categories. These numbers reflect the (most recent available) estimates on 2018-12-31.

Vaccination progress dataset covid_de_vaccines.csv:

• date: calendar date of vaccination

• doses, doses_first, doses_second: Daily count of administered doses: total, 1st shot, 2nd shot.

• pfizer_cumul, moderna_cumul, astrazeneca_cumul: Daily cumulative number of administered vaccinations by manufacturer.

• persons_first_cumul, persons_full_cumul: Daily cumulative number of people having received their 1st shot and full vaccination, respectively.

Acknowledgements

All the data have been extracted from open data sources which are being gratefully acknowledged:

• The [Robert ...

The global vaccine market is showing some escalating growth and it is expected that it will reach total revenues of nearly ** billion U.S. dollars by 2020. That would be almost double the size the market had back in 2014. Driver of the growth is the increase of various infectious diseases like influenza, swine flu, hepatitis, tuberculosis, diphtheria, Ebola, and meningococcal and pneumococcal diseases. Leading manufacturers of vaccines are big pharma companies like GlaxoSmithKline, Merck & Co., and Pfizer.

How vaccines work

The concept behind the functioning of vaccines - also known as immunizations - is relatively simple: inject a weakened form, or a fragment, of a disease to a person so the body learns to produce antibodies or to start other processes of immunity. As a result, the person’s body is ready to fight the same infection next time. By this way, infectious diseases which once had high death rates like polio and smallpox have been nearly eradicated. Others like measles, mumps, and whooping cough, are mostly under control and larger epidemics have been successfully prevented. While some immunizations last lifelong, others have to be renewed to stay efficient. Despite the obvious success of immunizations and their huge role for public health, there are discussions about the safety and consequences of vaccines in the U.S. and many other countries.

The vaccine market

At this moment, Pfizer’s Prevnar 13 is the world’s leading vaccine product, generating around *** billion U.S. dollars of revenue. Prevnar 13 is a vaccine for the prevention of invasive disease caused by ** streptococcus pneumoniae strains and can be used in children and adults. The United States are the world’s largest national market for vaccines, while North America is, accordingly, the largest regional market. The global vaccine market is largely dominated by vaccines which are administered intramuscularly. These vaccines make up over half of global revenues, while vaccines which are administered subcutaneously make up around *** fifth of the market. Other common routes of administration are oral or intravenous.